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ABSTRACT 
 
In this study we report the first isolation of VanA-type vancomycin-resistant Enterococcus faecalis strains 
from two different patients hospitalized in the same intensive care unit at the hospital of Universidade 
Federal do Triângulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.  
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Vancomycin-resistant enterococci (VRE) have emerged as 
important nosocomial pathogens worldwide in the last two 
decades, particularly in USA (3). In Brazil, the frequency of 
VRE isolation in hospitals has also increasing significantly, 
since the first report in 1998 (6).  
Glycopeptide resistance in enterococci is associated with a 
variety of phenotypes but VanA-type VRE is the most 
prevalent in Brazil (9). VRE strains with this phenotype 
express high-level resistance to vancomycin and teicoplanin 
and harbored a mobile genetic element Tn1546 that carries 
vanA gene cluster responsible by glycopeptide resistance (5).  
In this study we report the first isolation of VanA-type 
VRE strains from two different patients hospitalized in the ICU 
at the hospital of the Universidade Federal do Triângulo 
Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.  
The first VRE strain was isolated on March 11th, 2006, 
from an abdominal aorta catheter of a patient who underwent 
abdominal aortic aneurysmectomy. This patient, a 74-year-old 
male, was admitted to the hospital on March 5th, 2006, for the 
surgery. Postoperatively, he stayed in ICU for three days and 
was treated prophylactically with cephalothin. One day after 
left the ICU, he died by broncoaspiration. The second VRE 
strain was isolated on April 3rd, 2006, from a tracheal secretion 
of a 60-year-old male who was hospitalized since January, 
2006, with pneumonia. In February, as the patient developed 
urinary tract infection and septic shock, he was transferred to 
ICU. He remained at ICU for fifty-nine days. This patient 
recovered and left the hospital at the end of April. Prior to 
isolation of VRE, the patient had been treated with 
ciprofloxacin, ampicillin/sulbactam, cefepim, 
imipenem/cilastin and vancomycin. These two patients were 
hospitalized in the same room in the ICU-adult for a period of 
three days in common. 
The isolates were identified to species level by 
conventional biochemical tests (8). Minimum inhibitory 
concentration (MIC) for vancomycin was determined by broth  
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dilution test and susceptibility to ampicillin, penicillin, 
ciprofloxacin, chloramphenicol, erythromycin, gentamycin, 
streptomycin, tetracycline and teicoplanin was performed by 
disk diffusion method (4). E. faecalis ATCC 29212 and E. 
faecalis ATCC 51299 were used as controls. 
Genomic DNA of the microorganisms was extracted by 
mechanical disruption of cells (1). Polymerase chain reaction 
(PCR) was performed in order to confirm phenotypic species 
level identification (7) and multiplex PCR to determine the van 
genotype (13). Control strains were Enterococcus casseliflavus 
NCTC 12361, E. faecium NCTC 7171, E. faecalis NCTC 775, 
E. gallinarum NCTC 12359, and E. faecium BM 4147 vanA 
genotype. 
Tn1546-like elements and vanRSHAX regions were 
amplified by Long-PCR (L-PCR) according to Palepou et al. 
(10) using the Long PCR Enzyme Mix (Fermentas, Glen 
Burnie, MD, USA). First, a single primer (P1) complementary 
to the inverted repeats regions flanking the transposon was 
used for amplified Tn1546-like elements. Subsequently, the 
amplified Tn1546-like element was the template for L-PCR of 
vanRSHAX genes using primers P2 and P3. The L-PCR 
products were analysed on 1% agarose gel. 
Isolates were typed by pulsed-field gel electrophoresis 
(PFGE) after SmaI-digestion of DNA (2) in a Gene Navigator 
apparatus (Amersham, Uppsala, Sweden) at 180V for 25h, at 
7ºC with pulses of 20s for 10h, 8s for 10h and 3s for 5h. DNA 
banding patterns were analysed using previously described 
criteria (12). 
Both VRE isolates were identified as Enterococcus 
faecalis and expressed high-level resistance to vancomycin 
(MIC ≥ 256 µg/ml). They showed the same antimicrobial 
susceptibility profile, characterized by resistance to 
ciprofloxacin, chloramphenicol, erythromycin, tetracycline and 
teicoplanin. The isolates showed susceptibility to ampicillin, 
penicillin, gentamicin and streptomycin.  
According to multiplex PCR assay both VRE isolates 
harbored the vanA gene in the intact Tn1546-like element. The 
vanRSHAX genes were also detected by Long-PCR.  
       The molecular typing has disclosed the same PFGE pattern 
for both isolates (Fig. 1), suggesting clonal dissemination of 
this strain in ICU. On the other hand, we founded seven 
different bands comparing the PFGE profile of these VRE 
strains, isolated in 2006, with the clone predominant spread in 
some states of Brazil (strains isolated from 1998 to 2000) (9). 
As the criteria proposed by Tenover et al. (12) for analyzing 
the relationship among strains refer to those obtained for a 
short period of time, the difference in PFGE profile could not 
signify that they are unrelated. 
In Minas Gerais state, the prevalence of VRE seems to be 
lower than that observed in other states, such as São Paulo and 
Rio Grande do Sul, since there is only one other report 
describing the isolation of a VRE strain in the Uberlândia city 
in 2003 (11).  
In conclusion, our data showed that the VRE was 
transferred horizontally between patients in the same ICU room 
emphasizing that is very important to monitor their occurrence 
in hospital environment and to take measures to prevent the 
dissemination of nosocomial VRE among several patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. PFGE patterns after SmaI digestion of total DNA 
extracted from the VRE strains. Lanes 1: Lambda ladder PFG 
marker (New England Biolabs); 2: Clone of vancomycin-resistant 
E. faecalis predominant in Brazil; 3-4: Clinical isolates of 
vancomycin-resistant E. faecalis from Uberaba, Minas Gerais. 
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